A Randomised, Double-blind, Placebo-controlled, Phase III Study of Adjuvant Saruparib (AZD5305) in Patients With BRCAm Localised High-Risk Prostate Cancer Receiving Radiotherapy With Androgen Deprivation Therapy (EvoPAR-Prostate02).
Latest Information Update: 24 Jul 2025
At a glance
- Drugs Saruparib (Primary) ; Abiraterone; Prednisolone; Prednisone
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- Acronyms EvoPAR-PR02
- Sponsors AstraZeneca
Most Recent Events
- 11 Jul 2025 Planned initiation date changed from 30 May 2025 to 15 Jul 2025.
- 08 May 2025 New trial record